SIGNED AN INVESTMENT AGREEMENT WITH U.S. INVESTOR GLOBAL CORPORATE FINANCE

Trieste, 31 July 2025 – Ulisse Biomed S.p.A. (“UBM” or the “Company” or the “Group”), an Italian healthcare biotech company operating in the fields of diagnostics, theranostics and therapeutics, announces that today has signed an investment agreement (the “Agreement”) with the U.S. based entities Global Corporate Finance (the “Investor”) and Sterling Atlantic, LLC (“SAP”). Under the Agreement, the Investor has undertaken to subscribe, in more tranches and exclusively upon request of the Company, newly issued ordinary shares of UBM for an aggregate amount of up to Euro 10,000,000 (ten million), over a period of 30 months. The Agreement also provides for the issuance to the Investor of warrants (“Warrant”) exercisable, in whole or in part, at any time within five years from the issue date, at a subscription price of Euro 2.04 per share. The signing of the Agreement will allow the Company to continue to be able to get, with the flexibility that this tool offers, a large amount of financial resources to cover the liquidity needs needed to carry out the business plan and develop the activities planned in its strategic guidelines, within the time frame covered by the Agreement.